Activation of the complement protein C3 in human gastric cancer (GC) is characterized by the localized buildup of C3 and its effectors, as well as a decrease in plasma C3 levels, which appears to contribute to tumour progression and poor prognosis in patients with GC [39]. The gene discussed is C3; the disease is gastric cancer.